Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and ...

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or ...

GLP-1 supplement makers claim that their products work similarly to weight loss injections like Ozempic. Here's what experts ...

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.

Agents like semaglutide show promise for treatment of substance use disorders. Inaccessibility of GLP-1 agonists due to high ...

GLP-1 receptor agonists are being recommended on social media, raising questions about who can see the content and what the ...